N4 Pharma (GB:N4P) has released an update.
N4 Pharma PLC has successfully secured £630,000 through the issue of new shares, aiming to propel its pharmaceutical endeavors, including the development of Nuvec®, a novel delivery system for cancer and vaccine treatments. The funds are earmarked for advancing key projects such as a proof of concept for an IBD treatment, co-marketing technologies with SRI, and obtaining approvals for ECP105. These initiatives are expected to offer significant value and enhance the company’s intellectual property portfolio.
For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.
